

Tissue Factor, Tissue Factor Pathway Inhibitor and Factor VII Activity in Cardiovascular Complicated Type 2 Diabetes Mellitus

Rehab S. El-Hagracy,¹ Gihan M. Kamal,¹ Inas M. Sabry,¹ Abeer A. Saad,²
Nahla F. Abou El Ezz,³ Hesham A.R. Nasr⁴

Abstract:

Objectives: Tissue factor (TF) is the main initiator of the extrinsic coagulation pathway through factor VII (FVII) activation, which is physiologically inhibited by tissue factor pathway inhibitor (TFPI). Alteration of this pathway has been described in Type 2 diabetes mellitus (T2DM). The aim of this study is to assess TF and TFPI plasma levels and FVII coagulant activity (FVIIa) in T2DM in relation to cardiothrombotic disease and their correlation to metabolic and clinical behavior of the patients.

Methods: The study was conducted on 80 T2DM patients divided to accordingly; groupI: 40 patients without a history or clinically detected heart disease, and groupII: 40 patients with a history of myocardial infarction compared to 30 controls. The patients were recruited from Ain Shams University diabetes clinic from September 2007 to February 2009 after informed consent was obtained. Peripheral blood samples were taken for measurement of plasma TF and TFPI levels using ELISA technique and quantitative FVIIa using FVII deficient plasma.

Results: Plasma levels of TF, TFPI and FVIIa were significantly higher in T2DM patients compared to the controls ($p<0.001$). TF (236.50 ± 79.23) and TFPI (242.33 ± 85.84) were significantly

higher in group II, compared to group I (150.33 ± 81.16), (152.8 ± 82.46), ($p<0.001$). TF and TFPI were significantly correlated to body mass index and glycemic control. Also, TF and TFPI were significantly higher in hypertensives ($p=0.001$) and dyslipidemics ($p=0.006$) but not in smokers ($p=0.64$), ($p=0.11$) respectively.

Conclusion: There was a correlation between high TF, TFPI plasma levels, FVIIa activity and cardiothrombotic complications in T2DM especially in the presence of high risk factors such as poor glycemic control, dyslipidemia and obesity. Future target therapy against TF may be beneficial for T2DM patients.

From the ¹Internal Medicine Department, Ain Shams University, Cairo; ²Clinical Pathology Department, Ain Shams University, Cairo; ³Community, Environmental and Occupational Medicine Department, Ain Shams University, Cairo; ⁴Cardiology Department National Heart Institute, Cairo, Egypt.

Received: 27 Dec 2009

Accepted: 02 Mar 2010

Address correspondence and reprint request to: Dr. Rehab Saleh El-Hagracy, Lecturer of Internal Medicine/Hematology Department, Ain Shams University, Cairo, Egypt.

E-mail: rehabelhagracy@hotmail.com

doi:10.5001/omj.2010.52

Introduction

Type 2 diabetes mellitus (T2DM) is associated with accelerated atherosclerosis, endothelial damage and a high tendency to thrombotic complications including peripheral vascular disease, cardiovascular events and stroke.^{1,2,3,4} The T2DM procoagulant state can be contributed to abnormalities of several plasma proteins involved in blood coagulation and platelet activation.⁵ Thrombotic myocardial infarction may be secondary to complicated or ruptured atherosclerotic plaques with further exposure of procoagulant proteins that initiate blood coagulation or due to contact between blood and damaged endothelium.^{6,7}

Tissue factor (TF) is a key enzyme in extrinsic coagulation pathway, present in the adventitia of normal blood vessels, atherosclerotic plaques, in addition to a circulating pool in the blood.⁸ The activation of extrinsic coagulation pathway is mediated via the binding of FVII to TF to form a TF-FVIIa complex, further activation of factor X, IX, XI, the formation of prothrombinase complex and thrombin generation.⁹

On the other hand, TFPI is a 40-kDa endogenous protein synthesized by the vascular endothelium and is present in plasma,

platelets and bound to endothelial heparan sulphates.¹⁰ TFPI inhibits TF-initiated coagulation by binding with activated factor X (FXa), then TFPI-Xa complex binds to the TF/FVIIa complex and modifies their activity.¹¹ Altered TF/TFPI ratio have been related to the development of atherosclerosis, acute coronary syndrome, disseminated intravascular coagulation, sepsis, or thrombotic complications of malignancies.^{12,13}

Although T2DM is associated with increased systemic blood coagulation activity, evidence that activated coagulation or inhibited fibrinolysis has clinical implications in patients with T2DM remains circumstantial.^{14,15}

In chronic hyperglycemia, the binding of advanced glycated end products to their specific receptors induces an intravascular oxidative stress response, leading to TF expression in vitro.¹⁶ TF was found to be an independent factor related to microvascular diabetic complications (microalbuminuria, retinopathy) and neuropathy, and it reflects endothelial dysfunction, rather than procoagulant activity.¹⁷

Also, increased TFPI activity was demonstrated in patients with diabetes particularly in patients with microalbuminuria.¹⁸ Increases in TFPI reflected endothelial dysfunction or altered binding of TFPI to the endothelium by glucosaminoglycans

because TFPI is mainly produced by vascular endothelium.¹⁹ Plasma FVII levels depend on serum lipids and obesity index, so it is mostly elevated among T2DM patients who are often obese, and frequently present with dyslipidemia.²⁰

The aim of the present work is to assess TF and TFPI plasma levels together with FVII coagulant activity (FVIIa) in T2DM with and without cardiovascular complications and correlate the results with metabolic and clinical behavior of the patients.

Methods

The study included 80 patients with T2DM and 30 healthy controls of matched age and sex who were recruited from the Diabetes Clinic of Internal Medicine of Ain Shams university hospital from September 2007 to February 2009. The patients were subdivided into two subsets. Group I: 40 patients without a history, clinical or electrocardiography (ECG) findings suggesting the presence of heart disease, and group II; 40 patients with a history of myocardial infarction as documented by their ECG, Echocardiography or coronary catheter. The exclusion criteria included DM of less than 10 years, history of myocardial infarction within the last three months, congestive heart failure, surgery or trauma within the previous three months, known malignant, renal or hepatic diseases, heparin or oral contraceptive pills intake. All studied subjects gave their informed consent and the study was approved by the Ain Shams University Hospital Ethical Committee.

A full detailed history regarding diabetes history, vascular complications, hypertension, smoking and history of drug intake including heparin, oral anticoagulants and antiplatelet drugs was obtained. Careful clinical and cardiological examinations including ECG and echocardiography, and revising previously done stress ECG and coronary angiography were performed. Body mass index was calculated as BMI=body weight in Kg divided by (height in meter).²

Laboratory investigations were conducted to determine prothrombin time (PT) and activated partial thromboplastin time using (SYSMEX CA-1500, Dade Behring, Germany), fasting and postprandial serum glucose level (using glucose oxidase method), serum cholesterol, triglycerides (TG), low density lipoprotein (LDL) and high density lipoprotein (HDL) levels using Synchron CX-7 (Beckman, Switzerland), glycated hemoglobin (HbA1C) using Stanbio Glycohemoglobin (STANBIO, Italy), measurement of plasma TF and TFPI using enzyme linked immunosorbant assay (ELISA) technique, and measurement of FVII coagulation activity (FVIIa) in the plasma using FVII deficient plasma. 2 ml of venous blood were collected from patients and controls and was anticoagulated with buffered sodium citrate (3.2%) in the proportion of 9:1. Plasma were separated and kept at -70 until the time of analysis.

The plasma level of TF was determined by means of the AssayMax Human TF ELISA Kit (GENTAUR, Belgium, catalogue number: ET1002-1). A quantitative sandwich enzyme immunoassay technique was employed. A polyclonal antibody specific for TF was pre-coated onto well microplate. The TF in standards and samples was sandwiched by the immobilized antibody and the biotinylated polyclonal antibody specific for TF, which is recognized by a streptavidin-peroxidase conjugate. All unbound material was then washed away and a peroxidase enzyme substrate was added. The color development was stopped and the intensity of the color was measured at wavelength 450 nm and it was related to the standard curve. The level of TF was expressed in ng/ml.

Plasma level of TFPI was measured by means of AssayMax Human TFPI ELISA kit (GENTAUR, Belgium, catalogue number: ET1005-1). This assay employs a quantitative sandwich enzyme immunoassay technique. A murine antibody specific for TFPI was pre-coated onto well microplate. TFPI form the standards and samples were sandwiched by the immobilized antibody and a polyclonal antibody specific for TFPI, which is recognized by a peroxidase conjugate. All unbound material was then washed away and a peroxidase conjugate substrate was added. The color development was stopped and the intensity of the color was measured at wave length 450 nm and was related to a standard curve. The level of TFPI was expressed in pg/dl.

Quantitative FVII coagulant activity was determined based on the prothrombin time assay using coagulation FVII-deficient plasma (Dade Behring, Germany). Frozen citrated plasma was diluted 1:20 and the assay procedure was performed according to the manufacturer instructions. A standard curve was prepared using 20 normal plasma pool mixed with the deficient plasma. The test was performed on SYSMEX CA-1500 (Dade Behring, Germany) Instrument and the results were related to the standard curve. FVIIa is expressed as a percentage (%).

The data was analyzed using SPSS statistical package version 12. Descriptive statistics including mean and SD were analyzed using the Chi-square test (χ^2). The Fisher exact test was performed in tables containing values less than 5 and the Pearson's correlation test (t-test) performed to compare independent samples and correlation study. Probability or p value of <0.05 was considered statistically significant, while p value ≤ 0.001 was considered statistically highly significant.

Results

The study was conducted on 80 T2DM patients; 42 males and 38 females with a 1.1:1 male to female ratio, with mean age (years) of 49.5 ± 8.6 against 30 controls, 16 males and 14 females with a 1.14:1

male to female ratio with mean age (years) of 47.9 ± 6.1 and they were matched in terms of age and sex. The clinical and metabolic parameters of the patients and controls are demonstrated in Table 1.

Out of the 80 patients, there were 33 (41.25%) hypertensive, 18 (22.5%) smokers, and 45 (56.25%) dyslipidemics (cholesterol >200 mg/dl, triglycerides >150 mg/dl).

A comparison between the patients and controls regarding TF, TFPI and FVIIa is demonstrated in Table 2.

TF and TFPI plasma levels as well as FVIIa were statistically significantly higher in the patient group (193.41 ± 90.61 ng/ml, 197.56 ± 94.88 pg/ml, 108.25 ± 26.72 %) respectively compared to the controls (72.89 ± 31.283 ng/ml, 40.11 ± 13.16 pg/ml, 75.79 ± 11.2 %) respectively ($p < 0.001$). A comparison between group I and II in terms of plasma levels of TF, TFPI, and FVIIa is highlighted in Table 3.

Table 1: Clinical and metabolic parameters of patients and control.

Parameter	Number (%)	
	Controls	Type 2DM Patients
Men	16 (53.3%)	42 (52.5%)
Smokers	-	18 (22.5%)
Hypertensive	-	33 (41.25%)
Dyslipidemics	-	45 (56.25%)
Mean \pm SD		
Age (years)	47.9 ± 6.1	49.5 ± 8.6
BMI (Kg/M ²)	23.68 ± 1.76	32.78 ± 3.91
FBS (mg/dl)	82.68 ± 8.41	197.40 ± 62.00
2pp (mg/dl)	118.05 ± 8.79	284.90 ± 87.49
HBA1C	5.15 ± 0.64	9.85 ± 1.98
Cholesterol (mg/dl)	151.52 ± 9.25	218.88 ± 53.41
Triglycerides (mg/dl)	116.57 ± 14.75	165.33 ± 49.52
HDL	45.73 ± 4.91	41.61 ± 5.72
LDL	91.10 ± 19.06	130.10 ± 41.57

Both groups I and II were matched in terms of gender ($p=0.43$) and age ($p=0.18$). TF and TFPI plasma levels were significantly higher in cardiovascular complicated patients (236.50 ± 79.23 ng/ml, 242.33 ± 85.84 pg/ml) compared to non complicated patients (150.33 ± 81.16 ng/ml, 152.8 ± 82.46 pg/ml), ($p < 0.001$). However FVIIa tended to be higher among complicated cases but there was no significant statistical difference ($p=0.65$).

A correlation between plasma levels of TF, TFPI and FVIIa among studied subjects is demonstrated in Table 4.

Table 2: Comparison between patients and controls as regards the TF, TFPI, and FVIIa.

	Cases (mean \pm SD) n=80	Control (mean \pm SD) n=30	t	p
TF (ng/ml)	193.41 ± 90.61	72.89 ± 31.28	5.670	**<0.001
TFPI (pg/ml)	197.56 ± 94.88	40.11 ± 13.16	7.181	**<0.001
FVIIa (%)	108.25 ± 26.72	75.79 ± 11.21	5.135	**<0.001

$p > 0.05$: non significant; * $p \leq 0.05$: significant; ** $p \leq 0.001$: highly significant.

TF plasma level was significantly correlated to TFPI plasma level and FVIIa. Moreover, a significant correlation between TFPI plasma level and FVIIa was found among all the studied subjects ($p < 0.001$). Correlations between plasma levels of TF, TFPI, FVIIa and different studied parameters among T2DM are highlighted in Table 5.

Table 3: Comparison between complicated and non complicated patients regarding demographic data and serum TF, TFPI & FVII levels.

Parameters	Complicated DM	Non Complicated DM	p value
Males No (%)	28(70%) $X^2=1.071$	24(60%)	0.43
Age (years) (mean \pm SD)	51 ± 8.6 $t=1.38$	49 ± 8.5	0.18
TF (ng/ml) (mean \pm SD)	236.50 ± 79.23 $t=4.16$	150.33 ± 81.16	**<0.001
TFPI (pg/ml) (mean \pm SD)	242.33 ± 85.84 $t=4.12$	152.8 ± 82.46	**<0.001
FVIIa (%) (mean \pm SD)	109.83 ± 25.55 $t=0.46$	106.67 ± 28.2	0.65

$p > 0.05$: non significant; * $p \leq 0.05$: significant; ** $p \leq 0.001$: highly significant.

There were significant positive correlations between TF plasma level and BMI ($p=0.04$), FBS ($p=0.01$), HBA1C ($p < 0.001$) and LDL ($p < 0.001$). On the other hand, TFPI plasma level showed significant correlation to FBS ($p=0.007$), 2hPP ($p=0.04$), HBA1C ($p=0.008$), LDL ($p=0.003$) and HDL ($p=0.02$).

Table 4: Correlations between TF, TFPI, and Factor VIIa among type 2 diabetic patients.

Correlation parameters	r	p
TF and TFPI	0.611	**<0.001
TF and FVIIa	0.828	**<0.001
TFPI and VIIa	0.457	**<0.001

**P<0.001:highly significant

FVIIa was statistically significantly correlated to BMI ($p=0.006$), FBS ($p=0.003$), 2hPP ($p=0.04$), and HBA1C ($p<0.001$). The impact of Smoking, hypertension and dyslipidemia on plasma levels of TF, TFPI and FVIIa is shown in Table 6.

Table 5: Correlations between TF and TFPI plasma levels, FVIIa and studied parameters among type 2 diabetic patients

Parameters		TF	TFPI	FVIIa
BMI	r	0.258	-0.06	0.34
	p	0.04*	0.65	0.006**
FBS	r	0.32	0.34	0.37
	p	0.01*	0.007**	0.003**
2hPP	r	0.23	0.26	0.27
	p	0.08	0.04*	0.04*
HBA1C	r	0.54	0.34	0.47
	p	<0.001**	0.008**	<0.001**
HDL	r	-0.16	-0.31	-0.11
	p	0.23	0.02*	0.39
LDL	r	0.48	0.37	0.23
	p	<0.001**	0.003**	0.08

p>0.05: non significant,* p≤0.05:significant,**p≤0.001:highly significant.

T2DM patients with dyslipidemia had significantly higher TF (225.43 ± 92.11 ng/dl) compared to non dyslipidemics (148.6 ± 67.66 ng/dl), ($p=0.001$). Also, TFPI was higher in patients with dyslipidemia (225.71 ± 79.49 pg/dl) compared to non-dyslipidemics (158.16 ± 102.02 pg/dl), but the difference was not statistically significant ($p=0.006$).

Although FVIIa was higher among dyslipidemic compared to non dyslipidemics, the difference was not statistically significant ($p=0.184$). Moreover, the diabetic hypertensive patients exhibited significantly higher plasma level of TF ($p<0.001$) and TFPI ($p=0.006$) as well as FVIIa ($p=0.02$) compared to non-hypertensives. However, smoking did not significantly affect TF ($p=0.64$), TFPI ($p=0.11$) plasma levels or FVIIa ($p=0.51$).

Table 6: Impact of smoking, hypertension and dyslipidemia on TF, TFPI plasma levels and FVIIa.

Parameter (Mean ± SD)	TF (ng/ml)	TFPI (pg/ml)	FVIIa (%)
Smoking: no Yes (18)	179±107.51	246.87±133.86	102.5±30.58
	No (62)	195.57±88.74	189.98±86.68
	t=0.468 P=0.64	t=1.600 P=0.11	t=0.650 P=0.51
Hypertension: no Yes (33)	262.82±69.49	239.56±59.86	118.04±24.24
	No (47)	150.27±74.25	171.45±103.61
	t=5.848 P<0.001	t=2.864 P=0.006	t=2.320 P=0.02
Dyslipidemia: no Yes (45)	225.43 ± 92.11	225.71± 79.49	112.14± 28.06
	No (35)	148.6 ± 67.66	158.16± 102.02
	t=3.540 P=0.001	t=2.882 P=0.006	t=1.344 P=0.184

Discussion

Cardiovascular complications in T2DM patients related to several pathogenic mechanisms including the hypercoagulable state especially among poorly controlled DM patients.

The aim of the present work was to assess plasma levels TF and TFPI together with FVIIa in T2DM with and without cardiovascular complications and correlated the findings with metabolic and clinical behavior of the patients.

The circulating TF is considered a marker for vascular injury and a source of procoagulant activity, when expressed on the surface of circulating microparticles.^{21,22,23,9}

This study has demonstrated that not only plasma levels of TF but also TFPI and FVIIa were also higher in T2DM patients compared to the healthy controls. This is in agreement with previous studies.^{10,24-28} The heightened TF and TFPI levels probably reflect the increase of TF and TFPI activity in diabetic patients.

TFPI is mostly bound to vascular endothelium and only 20-30% is free.²⁹ However, its level shows diurnal variation which is parallel to FVII activity to maintain homeostatic coagulation mechanisms in healthy subjects.³⁰ Higher morning levels of TFPI demonstrated in cardiac patients following coronary spasm that can be a counter balance mechanism to prevent coagulation.³¹ This work demonstrated a significant positive correlation between TFPI plasma level and FVIIa among all the studied subjects.

Moreover, a significant positive relationship between TF and TFPI plasma level was noted in the studied subjects. This is in line with Falciani et al. who observed a positive correlation between TF

and TFPI levels in ischemic heart disease patients.³² While Gosk-Bierska et al. confirmed this correlation among atherosclerotic peripheral vascular disease.³³ Thus, increased TFPI levels in this condition may be related to activation of TF-dependent pathway in attempt to compensate for the hypercoagulable state but was not sufficient to overcome elevated TF.³²

In this study, cardiovascular complicated T2DM patients had significantly higher TF and TFPI plasma levels compared to uncomplicated patients. This finding was confirmed by Boden et al. and Krupinski et al.^{34,35} Moreover Sommeijer et al. noticed higher soluble TF levels in T2DM with microvascular complications.¹⁷ Activated FVII was significantly higher among complicated T2DM patients.^{10,24,28} However in this study, FVIIa tended to be elevated in cardiovascular complicated patients but the difference did not reach statistical significance.

Obesity is known to be a risk factor for heart diseases and is an obstacle in proper glycemic control in diabetics.³⁶ Obesity enhances thrombotic tendency through up regulation of TF, altered expression of proteins participating in the coagulation cascade as well as atherosclerosis.³⁷ Thus confirming a preliminary report.¹⁰ In this study, increased BMI was found to be significantly correlated with raised TF plasma level and FVIIa. Moreover, Kopp et al. found significantly high TF and VII but lower TFPI among morbidly obese diabetics.³⁸

The importance of hyperglycemia in the pathogenesis of diabetic complications and the role of proper glycemic control in reducing mortality and morbidity in diabetic patients have emerged over the past years. Derosa et al. and Turu et al. detected that hyperglycemia accelerates atherogenesis and potentially increases the risk of thrombotic complications.^{39,40} Raised blood glucose with hyperinsulinemia induce a marked rise in TF activity, TF expression, FVIIa T2DM.⁵ On the other hand, proper glycemic control reduces TF activity and FVIIa with further reduction in the procoagulant state.^{34,41} In this study, as previously recorded, high plasma levels of TF, TFPI and FVIIa were significantly correlated with fasting blood glucose and HBA1C.^{25,28} T2DM patients frequently present with dyslipidemia.

Dyslipidemia altered TF and TFPI expression in atheromatous plaque to favoring thrombosis.⁴² Previously, it has been shown that leukocyte and endothelial cell cultures incubated with triglyceride (TG)-rich chylomicrons and very low-density lipoproteins activates FVII, and TF expression.^{43,44} In this study, diabetic dyslipidemic patients had significantly higher TF and TFPI plasma level compared to non dyslipidemic patients, which echoes previous results.^{8,28}

In addition, the hypertensive diabetic patients in this study had higher TF and TFPI levels than non hypertensives. Similar

results were reported by Sommeijer et al. in 2006.¹⁷ Therefore, proper control of blood pressure may reduce TF levels, resulting in further reduction in cardiovascular complications.

The effect of smoking was contradictory. Contrary to Hölschermann et al.⁴⁵ and Barua et al.⁴⁶ smoking was not significantly correlated to TF, FVII nor TFPI levels among the studied patients, which is also in line with a previous study by Sobol et al.⁴⁷

Conclusion

Plasma levels of TF, TFPI and FVIIa were significantly higher in T2DM. In addition, TF and TFPI were significantly higher in cardiovascular complicated patients. The positive correlation of the procoagulant markers (TF/FVIIa) and blood glucose, HbA1c, lipid profile and BMI reinforces the importance of their optimal control in T2DM patients. Furthermore, pharmacological control of plasma TF activity or augmenting TFPI activity may reduce thrombotic cardiovascular complications. Further studies with larger number of patients are needed to confirm these findings.

Acknowledgements

The authors reported no conflict of interest and no funding was received on this work.

References

1. Paoletti R, Bolego C, Poli A, Cignarella A. Metabolic syndrome, inflammation and atherosclerosis. *Vasc Health Risk Manag* 2006;2(2):145-152.
2. Laakso M, Lehto S. Epidemiology of risk factors for cardiovascular disease in diabetes and impaired glucose tolerance. *Atherosclerosis* 1998 Apr;137(Suppl):S65-S73.
3. Sowers JR, Lester MA. Diabetes and cardiovascular disease. *Diabetes Care* 1999 Apr;22(Suppl 3):C14-C20.
4. Gentile NT, Vaidyula VR, Kanamalla U, DeAngelis M, Gaughan J, Rao AK. Factor VIIa and tissue factor procoagulant activity in diabetes mellitus after acute ischemic stroke: impact of hyperglycemia. *Thromb Haemost* 2007 Nov;98(5):1007-1013.
5. Boden G, Rao AK. Effects of hyperglycemia and hyperinsulinemia on the tissue factor pathway of blood coagulation. *Curr Diab Rep* 2007 Jun;7(3):223-227.
6. Gutstein DE, Fuster V. Pathophysiology and clinical significance of atherosclerotic plaque rupture. *Cardiovasc Res* 1999 Feb;41(2):323-333.
7. Koenig W. Haemostatic risk factors for cardiovascular diseases. *Eur Heart J* 1998 Apr;19(Suppl C):C39-C43.
8. Sambola A, Osende J, Hathcock J, Degen M, Nemerson Y, Fuster V, et al. Role of risk factors in the modulation of tissue factor activity and blood thrombogenicity. *Circulation* 2003 Feb;107(7):973-977.
9. Mackman N. Role of tissue factor in hemostasis, thrombosis, and vascular development. *Arterioscler Thromb Vasc Biol* 2004 Jun;24(6):1015-1022.
10. Vambergue A, Rugeri L, Gaveriaux V, Devos P, Martin A, Fermon C, et al. Factor VII, tissue factor pathway inhibitor, and monocyte tissue factor in diabetes mellitus: influence of type of diabetes, obesity index, and age. *Thromb Res* 2001 Mar;101(5):367-375.
11. Pantaleev MA, Zarnitsina VI, Ataullakhhanov FI. Tissue factor pathway inhibitor: a possible mechanism of action. *Eur J Biochem* 2002 Apr;269(8):2016-2031.

12. Ardisso D, Merlini PA, Ariëns R, Coppola R, Bramucci E, Mannucci PM. Tissue-factor antigen and activity in human coronary atherosclerotic plaques. *Lancet* 1997 Mar;349(9054):769-771.
13. Creasey AA, Reinhart K. Tissue factor pathway inhibitor activity in severe sepsis. *Crit Care Med* 2001 Jul;29(7)(Suppl):S126-S129.
14. Eckel RH, Wassef M, Chait A, Sobel B, Barrett E, King G, et al. Prevention Conference VI: Diabetes and Cardiovascular Disease: Writing Group II: pathogenesis of atherosclerosis in diabetes. *Circulation* 2002 May;105(18):e138-e143.
15. Grundy SM, Hansen B, Smith SC Jr, Cleeman JI, Kahn RA; American Heart Association; National Heart, Lung, and Blood Institute; American Diabetes Association. Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. *Circulation* 2004 Feb;109(4):551-556.
16. Bierhaus A, Illmer T, Kasper M, Luther T, Quehenberger P, Tritschler H, et al. Advanced glycation end product (AGE)-mediated induction of tissue factor in cultured endothelial cells is dependent on RAGE. *Circulation* 1997 Oct;96(7):2262-2271.
17. Sommeijer DW, Hansen HR, van Oerle R, Hamulyak K, van Zanten AP, Meesters E, et al. Soluble tissue factor is a candidate marker for progression of microvascular disease in patients with Type 2 diabetes. *J Thromb Haemost* 2006 Mar;4(3):574-580.
18. Leurs PB, van Oerle R, Wolffenbuttel BH, Hamulyak K. Increased tissue factor pathway inhibitor (TFPI) and coagulation in patients with insulin-dependent diabetes mellitus. *Thromb Haemost* 1997 Mar;77(3):472-476.
19. Lindahl AK, Sandset PM, Abildgaard U. The present status of tissue factor pathway inhibitor. *Blood Coagul Fibrinolysis* 1992 Aug;3(4):439-449.
20. Lam KS, Ma OC, Bourke C, Chan LC, Janus ED. Genetic influence of the R/Q353 genotype on factor VII activity is overwhelmed by environmental factors in Chinese patients with Type II (non-insulin-dependent) diabetes mellitus. *Diabetologia* 1998 Jul;41(7):760-766.
21. Koyama T, Ohdama S, Aoki N. Plasma tissue factor reflects endothelial cell injury rather than upregulation of tissue factor expression. *Thromb Haemost* 1997 Aug;78(2):972.
22. Makin AJ, Blann AD, Chung NA, Silverman SH, Lip GY. Assessment of endothelial damage in atherosclerotic vascular disease by quantification of circulating endothelial cells. Relationship with von Willebrand factor and tissue factor. *Eur Heart J* 2004 Mar;25(5):371-376.
23. Falati S, Gross P, Merrill-Skoloff G, Furie BC, Furie B. Real-time in vivo imaging of platelets, tissue factor and fibrin during arterial thrombus formation in the mouse. *Nat Med* 2002 Oct;8(10):1175-1181.
24. Rao AK, Chouhan V, Chen X, Sun L, Boden G. Activation of the tissue factor pathway of blood coagulation during prolonged hyperglycemia in young healthy men. *Diabetes* 1999 May;48(5):1156-1161.
25. Leurs PB, Stolk RP, Hamulyak K, Van Oerle R, Grobbee DE, Wolffenbuttel BH. Tissue factor pathway inhibitor and other endothelium-dependent hemostatic factors in elderly individuals with normal or impaired glucose tolerance and type 2 diabetes. *Diabetes Care* 2002 Aug;25(8):1340-1345.
26. Song KS, Kim HK. Plasma levels of tissue factor antigen in patients with non-insulin-dependent diabetes mellitus. *Yonsei Med J* 2004 Feb;45(1):38-42.
27. Ludwig S, Dharmalingam S, Erickson-Nesmith S, Ren S, Zhu F, Ma GM, et al. Impact of simvastatin on hemostatic and fibrinolytic regulators in Type 2 diabetes mellitus. *Diabetes Res Clin Pract* 2005 Nov;70(2):110-118.
28. El-Ghoroury EA, El-Din HG, Abdel-Kader M, Ragab S. Study of factor VII, tissue factor pathway inhibitor and monocyte tissue factor in noninsulin-dependent diabetes mellitus. *Blood Coagul Fibrinolysis* 2008 Jan;19(1):7-13.
29. Kato H. Regulation of functions of vascular wall cells by tissue factor pathway inhibitor: basic and clinical aspects. *Arterioscler Thromb Vasc Biol* 2002 Apr;22(4):539-548.
30. Pinotti M, Bertolucci C, Portaluppi F, Colognesi I, Frigato E, Foà A, et al. Daily and circadian rhythms of tissue factor pathway inhibitor and factor VII activity. *Arterioscler Thromb Vasc Biol* 2005 Mar;25(3):646-649.
31. Misumi K, Ogawa H, Yasue H, Soejima H, Suefuji H, Nishiyama K, et al. Circadian variation in plasma levels of free-form tissue factor pathway inhibitor antigen in patients with coronary spastic angina. *Jpn Circ J* 1998 Jun;62(6):419-424.
32. Falciani M, Gori AM, Fedi S, Chiarugi L, Simonetti I, Dabizzi RP, et al. Elevated tissue factor and tissue factor pathway inhibitor circulating levels in ischaemic heart disease patients. *Thromb Haemost* 1998 Mar;79(3):495-499.
33. Gosk-Bierska I, Wysokini Ski W, Karnicki K, Adamiec R. Tissue factor, tissue pathway factor inhibitor and risk factors of atherosclerosis in patients with chronic limb ischemia: preliminary study. *Int Angiol* 2008 Aug;27(4):296-301.
34. Boden G, Vaidyula VR, Homko C, Cheung P, Rao AK. Circulating tissue factor procoagulant activity and thrombin generation in patients with type 2 diabetes: effects of insulin and glucose. *J Clin Endocrinol Metab* 2007 Nov;92(11):4352-4358.
35. Krupinski J, Turu MM, Font MA, Ahmed N, Sullivan M, Rubio F, et al. Increased tissue factor, MMP-8, and D-dimer expression in diabetic patients with unstable advanced carotid atherosclerosis. *Vasc Health Risk Manag* 2007;3(4):405-412.
36. Bastard JP, Maachi M, Lagathu C, Kim MJ, Caron M, Vidal H, et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. *Eur Cytokine Netw* 2006 Mar;17(1):4-12.
37. Pi-Sunyer FX. The relation of adipose tissue to cardiometabolic risk. *Clin Cornerstone* 2006;8(Suppl 4):S14-S23.
38. Kopp CW, Kopp HP, Steiner S, Kriwanek S, Krzyzanowska K, Bartok A, et al. Weight loss reduces tissue factor in morbidly obese patients. *Obes Res* 2003 Aug;11(8):950-956.
39. Derosa G, D'Angelo A, Tinelli C, Devangelio E, Consoli A, Miccoli R, et al. Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in diabetic and healthy subjects. *Diabetes Metab* 2007 Apr;33(2):129-134.
40. Turu MM, Krupinski J, Catena E, Rosell A, Montaner J, Rubio F, et al. Intraplaque MMP-8 levels are increased in asymptomatic patients with carotid plaque progression on ultrasound. *Atherosclerosis* 2006 Jul;187(1):161-169.
41. Abdel-Hafiz E, Vaidyula VR, Bagga S, London FS, Boden G, Rao AK. Elevated whole blood tissue factor procoagulant activity in diabetes mellitus. Vitamin E inhibits glucose induced tissue factor activity in vitro. *Blood* 2002;100:496a.
42. Zawadzki C, Susen S, Richard F, Haulon S, Corseaux D, Jeanpierre E, et al. Dyslipidemia shifts the tissue factor/tissue factor pathway inhibitor balance toward increased thrombogenicity in atherosclerotic plaques: evidence for a corrective effect of statins. *Atherosclerosis* 2007 Dec;195(2):e117-e125.
43. Kaneko T, Wada H, Wakita Y, Minamikawa K, Nakase T, Mori Y, et al. Enhanced tissue factor activity and plasminogen activator inhibitor-1 antigen in human umbilical vein endothelial cells incubated with lipoproteins. *Blood Coagul Fibrinolysis* 1994 Jun;5(3):385-392.
44. McGee MP, Foster S, Wang X. Simultaneous expression of tissue factor and tissue factor pathway inhibitor by human monocytes. A potential mechanism for localized control of blood coagulation. *J Exp Med* 1994 Jun;179(6):1847-1854.
45. Hölschermann H, Terhalle HM, Zakei U, Maus U, Parviz B, Tillmanns H, et al. Monocyte tissue factor expression is enhanced in women who smoke and use oral contraceptives. *Thromb Haemost* 1999 Dec;82(6):1614-1620.
46. Barua RS, Ambrose JA, Saha DC, Eales-Reynolds LJ. Smoking is associated with altered endothelial-derived fibrinolytic and antithrombotic factors: an in vitro demonstration. *Circulation* 2002 Aug;106(8):905-908.
47. Sobol AB, Galar M, Mochecka A, Stańczyk L, Kłoczko J. [Tissue factor and its inhibitor in patients up to 50 years of age with ischemic stroke]. *Pol Merkur Lekarski* 2001 Feb;10(56):92-95.